Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CTO Realty Growth, Inc. (CTO) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / December 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CTO Realty Growth, Inc. ("CTO" or "the Company") (NYSE:CTO). Investors who purchased CTO securities prior to February 18, 2021, and continue to hold to the present, are encouraged to […]

Acadia Healthcare Company, Inc. (ACHC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / December 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Healthcare Company, Inc. ("Acadia" or "the Company") (NASDAQ:ACHC). Investors who purchased Acadia securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:

Flywire Corporation (FLYW) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / December 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flywire Corporation ("Flywire" or "the Company") (NASDAQ:FLYW). Investors who purchased Flywire securities prior to February 28, 2025, and continue to hold to the present, are encouraged to obtain additional

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / December 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain

13 Elk + Elk Attorneys Honored 2026 Ohio Super Lawyers, Rising Stars Awards

Elk + Elk, an Ohio personal injury firm based in Cleveland, is proud to announce that thirteen of its attorneys were included in the 2026 Super Lawyers® and Rising Stars lists. https://mma.prnewswire.com/media/2846807/Elk_plus_Elk_SuperLawyers2026.jpg This year, Elk + Elk sustained its exceptional performance with three attorneys earning spots on the most selective lists: — Jay Kelley and

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neogen Corporation (NEOG) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / December 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neogen Corporation ("Neogen" or "the Company") (NASDAQ:NEOG). Investors who purchased Neogen securities prior to January 5, 2025, and continue to hold to the present, are encouraged to obtain additional

Trends Affecting Recycled Packaging for Apparel Market 2026

Trends Affecting Recycled Packaging for Apparel Market 2026 According to Towards Packaging consultants, the global recycled packaging for apparel market is projected to reach significantly higher market value by 2034, rising from its current substantial base in 2025, and is expected to expand at a steady and consistent growth rate throughout the forecast period from

PB5STAR UNVEILS THE PB5 COSMIC

PB5star debuts the PB5 Cosmic, the all-day performance shoe for everyday playerswith Nebulon™ Core Technology PB5star, the premier performance-driven footwear, apparel, and game gear company for pickleball, tennis, padel, and other racquet sports enthusiasts, is thrilled to announce the launch of its Cosmic shoe with Nebulon Core Technology. With the Cosmic, PB5star is redefining the

Trethera Receives $2.7 Million NIH Grant, Validating the Potential of First-in-Class TRE-515 to Overcome KRAS Inhibitor Resistance in Lung Cancer

LOS ANGELES, Dec. 16, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the award of a new $2.7 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The award evaluates the combination of Trethera's lead drug

Trethera Receives $2.7 Million NIH Grant, Validating the Potential of First-in-Class TRE-515 to Overcome KRAS Inhibitor Resistance in Lung Cancer

Trethera Receives $2.7 Million NIH Grant, Validating the Potential of First-in-Class TRE-515 to Overcome KRAS Inhibitor Resistance in Lung Cancer GlobeNewswire December 16, 2025 LOS ANGELES, Dec. 16, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the award of a new

Scroll to Top